Chlorpromazine versus metiapine for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 5, 2015, Pages

  Zare, Morteza ^a   Bazrafshan, Azam ^a   Okhovati, Maryam ^a   Mazhari, Shahrzad ^a   Mousavi, Ruzbe ^b  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; METIAPINE; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL PROTOCOL; COMPARATIVE EFFECTIVENESS; DRUG EFFECT; DRUG SAFETY; DRUG STRUCTURE; HUMAN; MENTAL HEALTH; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84961967448     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011655     Document Type: Article

References (40)

1. Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3]
2. Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD007445.pub2;: CD007445]
3. Almerie MQ, Alkhateeb H, Essali A, Matar HE, Rezk E. Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006329;: CD006329]
4. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
5. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
6. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
7. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330(10):681-90. [PUBMED: 8107719]
8. Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. British Journal of Psychiatry: the journal of mental science 1980;137:383-6. [PUBMED: 7448479]
9. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
10. Dickenson R, Fenton M. Zotepine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD010644]
11. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
12. Dold M, Li C, Tardy M, Leucht S. Haloperidol versus first generation antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009831]
13. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
15. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
16. Elis O, Caponigro JM, Kring AM. Psychosocial treatments for negative symptoms in schizophrenia:Current practices and future directions. Clinical Psychology Review 2013;33:912-28. [DOI: 10.1016/j.cpr.2013.07.001]
17. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
18. Gallant DM, Bischop MP, Guerrero-Figueroa R. Metiapine: a new antipsychotic agent. Current Therapeutic Research 1970;12(12):794-7.
19. Gibson JP, Rohovsky MW, Newberne JW, Larson EJ. Toxicity Studies with metiapine. Toxicology and Applied Pharmacology 1973;25(2):220-9.
20. Grozier L. The third revolution in psychiatry: Fluphenazine decanoate. In: Ayd FJ editor(s). The Future of Pharmacotherapy: Drug Delivery System. Baltimore: International Drug Therapy Newsletter, 1973:97.
21. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
23. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
24. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
25. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
26. Ketteler HJ, Kuhn WL. Metiapine: Neuroleptic and peripheral autonomic attributes. Federation of American Societies for Experimental Biology 1970;29:620.
27. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001-5. [PUBMED: 16905632]
28. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
29. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
30. Leucht C, Kitzmantel M, Kane J, Leucht S, Chua WLLC. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2;: CD004278]
31. Liu X, De Han S. Chlorpromazine dose for people with schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007778;: CD007778]
32. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
33. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
34. Saha KB, Sampson S, Zaman RU. Chlorpromazine versus atypical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD010631]
35. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
36. Tardy M, Leucht S, Potapov A, Engel R, Dold M, Kissling W. Flupenthixol versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD009227]
37. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
38. World Health Organization. World Health Report. Geneva: World Health Organization, 2001.
39. World Health Organization. WHO Model List of Essential Medicines. 30. Vol. 17, World Health Organization, 2011.
40. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.